Neumora Therapeutics remains a high-risk, pre-revenue biotechnology firm entirely dependent on external capital to fund its precision psychiatry pipeline. The company faces significant valuation pressure following the clinical hold on its NMRA-266 program, whi...
Price trend, volume and key moving averages
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 14, 2026 | -$0.23+4.2% vs -$0.24 | — vs — |
Q2 2026 May 7, 2026 | -$0.30+6.3% vs -$0.32 | — vs — |
Q2 2026 Mar 16, 2026 | -$0.35-2.9% vs -$0.34 | — vs — |
Q4 2025 Nov 6, 2025 | -$0.35-2.9% vs -$0.34 | — vs — |
Biotech stocks are dominating today's unusual options volume list, with United Therapeutics Corporation (NASDAQ: UTHR), Neumora Therapeutics Inc (NASDAQ: NMRA), and Edgewise Therapeutics Inc (NASDAQ: EWTX) all attracting outsized attention in the options pits.
Favorable pre-clinical data reported for NMRA-215 with plan to submit IND in fourth quarter of 2026 and initiate Phase 1 study by end of 2026
Company plans to submit an IND in the fourth quarter of 2026 and to initiate Phase 1 study by the end of 2026 Company plans to submit an IND in the fourth quarter of 2026 and to initiate Phase 1 study by the end of 2026
Benchmark NMRA against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Neumora Therapeutics, Inc. Common Stock (NMRA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.50 | $92.62M | -0.34 | — | — | -121.21% | — | |
| $19.95 | $3.42B | 8.71 | 11.87% | 33.42% | 32.39% | — | |
| $20.50 | $1.51B | 6.21 | 18.52% | 80.56% | 30.03% | — | |
| $179.25 | $9.22B | -48.71 | 65.55% | -24.68% | -255.6% | — | |
| $295.51 | $8.24B | -21.92 | -100% | — | -34.15% | — | |
| $63.46 | $5.26B | 8.16 | 114.51% | -3.8% | — | — |
Neumora Therapeutics, Inc. Common Stock (NMRA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Neumora Therapeutics, Inc. Common Stock (NMRA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 14, 2026·SEC
Jul 27, 2026·SEC
Jun 15, 2026·SEC
Get notified when NMRA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Neumora Therapeutics, Inc. Common Stock (NMRA) stock FAQ — growth, dividends, profitability & financials explained
Neumora Therapeutics, Inc. Common Stock (NMRA) reported a net loss of $212.7M for fiscal year 2025.
Neumora Therapeutics, Inc. Common Stock (NMRA) has a return on equity (ROE) of -121.2%. Negative ROE indicates the company is unprofitable.
Neumora Therapeutics, Inc. Common Stock (NMRA) had negative free cash flow of $180.5M in fiscal year 2025, likely due to heavy capital investments.
